Source: BIOCENTURY Wugen: deploying memory NK cells against cancer AND TURNING ALLOGENEIC CAR T CELLS AGAINST T CELL MALIGNANCIES BY LAUREN MARTZ, SENIOR EDITOR MAY 17, 2021 | 2:08 PM…
Read MoreBiotech Executive and former Vice President of Research & Development at Takeda Pharmaceuticals brings notable expertise in cell therapies and strategic business development to the companyST. LOUIS, MO, and SAN…
Read More
Currently approved cellular therapies have been shown to effectively treat B-cell cancers, but there remains a significant unmet need for treating other cancers, including solid tumors.
Read More
BioWorld, David Ho, March 2021.
Read MoreST. LOUIS, MO, March 8, 2021 /PRNewswire/ – Wugen Inc., a clinical-stage biotechnology company developing novel universal natural killer (NK) and T-cell therapies for the treatment of cancer, today announced…
Read More
St. Louis Business Journal, Nathan Rubbelke, March 2021
Read MoreST. LOUIS, MO, March 2, 2021 /PRNewswire/ – Wugen Inc., a biotechnology company developing novel, universal allogeneic cell therapy platforms, today announced that it has entered into an exclusive license…
Read MoreST. LOUIS, March 1, 2021 – Wugen Inc., a biotechnology company developing novel, universal allogeneic off-the-shelf cell therapies, today announced the appointment of the company’s co-founder, Matt Cooper, Ph.D., as…
Read More
St. Louis Business Journal, Nathan Rubbelke, February 2021
Read MoreCopyright © 2022 Wugen. All Rights Reserved.
a COGNEO design
